期刊文献+

补肾泻肝汤对前列腺组织Smad2、Smad4表达的影响 被引量:2

Effect of Bushenxiegan Prescription on the Expression and Significance of Smad2 and Smad4 in Benign Prostatic Hyperplasia Tissues
下载PDF
导出
摘要 目的:观察补肾泻肝汤对实验性大鼠前列腺增生组织Smad2和Smad4表达的影响及意义。方法:去势加丙酸睾酮注射法复制大鼠前列腺增生模型,免疫组织化学法检测大鼠前列腺增生组织及正常前列腺组织Smad2和Smad4的表达。结果:模型组大鼠前列腺组织Smad2和Smad4表达水平均下调,不论Smad2还是Smad4,其在前列腺增生组织中的阳性表达率与正常前列腺组织及补肾泻肝汤组阳性表达率比较,差别有显著意义(P<0.05)。结论:Smad2和Smad4参与了前列腺增生的病理过程,补肾泻肝汤对前列腺增生组织Smad2和Smad4表达的改变有调节作用。 Objective:To observe the effect of Bushenxiegan prescription on the expression of Smad2 and Smad4 in benign prostatic hyperplasia tissues.Methods:S.D male rats were castrated,then subcutaneous injected testosterone propionate for 30 days.The expression of Smad2 and Smad4 levels in tissues of benign prostatic hyperplasia and normal prostate were detcted by immunohistochemiscal method.Results:The expression level of Smad2 in benign prostatic hyperplasia tissues and Smad4 is lower than that in normal prostate(P〈0.05).Conclusion:The expression level of Smad2 and Smad4 in benign prostatic hyperplasia tissues is lower than that in normal prostate.Both of them might be involved in the development of benign prostatic hyperplasia tissues.Bushenxiegan prescription can regulate the the expression of Smad2 and Smad4 of benign prostatic hyperplasia.
出处 《中医药学报》 CAS 2010年第1期14-17,共4页 Acta Chinese Medicine and Pharmacology
基金 国家自然科学基金(30973704) 湖北省自然科学基金(2007ABA057) 武汉市科技晨光计划(200850731346) 湖北省教育厅中青年项目(Q20081601)
关键词 前列腺增生 SMAD2 SMAD4 补肾泻肝汤 Benign prostatic hyperplasia Smad2 Smad4 Bushenxiegan prescription
  • 相关文献

参考文献6

二级参考文献41

  • 1顾方六.Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China[J].Chinese Medical Journal,2000(4):11-14. 被引量:17
  • 2顾方六,山岗志,王通生,薛兆英.北京城乡良性前列腺增生发病的差异[J].中华泌尿外科杂志,1995,16(7):387-390. 被引量:61
  • 3王涛,王润田,顾方六,王天根,冷泰俊,汪启明,黄翼然,魏强,欧阳骏,甘为民,肖正文,高居忠,庞自力,张文标,朱江,赵长林,张元芳,刘雨,张力青,宋涛,高江平,王玉杰,段国兰,陈曾德.营养素的摄入水平与前列腺癌关系的病例对照研究[J].中华泌尿外科杂志,1996,17(9):540-544. 被引量:8
  • 4[5]Gulig Z,Hobisch A,Cronaner MV,et al.Regulation of prostatic growth and function by peptide growth factors.Prostate,1996,28:392~405
  • 5[6]Grorge KI,Billie Jo MK,James AM,et al.Differentopl;immunoreactivity of epidermal growth factor receptor in benign,dysplastic and malignant prostatictissues.J Urol,1993,149:170~173
  • 6[7]Itoh N,Patel U,Skinner MK,Developmental and hormonal regulation of transforming growth factor-α and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells.Endocrinogy,1998,139:1369~1377
  • 7[8]J Deshukh N,scotson J,Dodson AR,et al.Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identifiedby immunohistochemistry.Br J Urol,1997,80:869~874
  • 8Miyazono K et al. J Cell Phyisol, 2001; 187(3):265.
  • 9Attisano L et al. Cur Opin Cell Biol, 2000,12(2) :235.
  • 10Massague J. Annu Rev Biochem, 1998, 67:753.

共引文献37

同被引文献22

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部